Interneuron dexfenfluramine advisory committee review to resume Nov. 16.

INTERNEURON DEXFENFLURAMINE ADVISORY COMMITTEE REDUX NOV. 16: FDA's Endocrinologic & Metabolic Drugs Advisory Committee will meet in November to resume discussion of the first long-term obesity therapy, oral dexfenfluramine, Lexington, Mass.-based Interneuron announced Oct. 3. Dexfenfluramine, tradenamed Redux, will be marketed by American Home Products if approved.